Recruiting nowPhase 2
What this trial is trying to do
The researchers are testing SL-28, a treatment made from donor immune cells that have not been genetically modified, to see whether targeted control of their immune activity can attack advanced solid tumours. The trial also examines how the treatment moves through the body and identifies doses for further testing.
The idea is that SL-28 could provide another treatment option for people whose cancers have progressed after chemotherapy or immunotherapy. The main measure is treatment-related side effects; the researchers will also look for signs of tumour control, but the trial is not designed to compare SL-28 with standard treatment.
Worth knowing: This is an open-label, non-randomised trial with an initial dose-escalation phase, so it is primarily testing safety and dose rather than establishing whether the treatment improves survival or delays cancer growth.
Written from the trial's own registry entry to explain what the researchers are testing and why. Nothing here is a result — this trial has not reported one — and it is not a view on whether the treatment works or on whether it would suit you.
| Registry number | NCT07341737 |
|---|---|
| Recruitment | Recruiting now |
| Phase | Phase 2 |
| Design | not randomised, open label |
| Taking part | 60 people (planned) |
| Who can join | aged 18 Years and over |
| Run by | Second Life Therapeutics |
| Started | |
| Main results expected | |
| Record last updated |
What is being tested
- Biological SL-28
What it is measuring
Number of participants with treatment-emergent adverse events
This is the trial's main question — the one it is designed and sized to answer. Anything else it reports is a secondary finding, and secondary findings are far more likely to be chance.
Phase 2. Tests whether the treatment works well enough to be worth a larger trial. Usually too small to prove it changes survival.
How the researchers describe it
Second Life Therapeutics is developing SL-28, an allogeneic, non-genetically modified cell-based therapy for the treatment of advanced solid tumours. The company has recently demonstrated a novel, non-genetic approach to modulate immune cell activity through targeted manipulation of the Universal Receptive System. The purpose of this open label, multi-center clinical trial is to evaluate the anti-tumor activity, safety, and pharmacokinetics, single-agent SL-28 in patients with a diverse array of solid tumors. The study includes an initial Phase 1 dose escalation to determine recommended dose(s) for expansion of SL-28 as a monotherapy and Phase 2 expansion cohorts. The study will enroll patients with advanced solid tumours, including those who failed previous lines of chemo- and immunotherapies.
Written by the trial’s sponsor, quoted from its ClinicalTrials.gov record.
What this trial is looking for
- Any genotype
- Metastatic
- Locally advanced
Read automatically from the criteria below, to make the list searchable. It is a summary of what the text mentions, not a decision about whether you qualify — and where the two disagree, the criteria are right and this is wrong.
Who the trial is looking for
Inclusion Criteria
- Ability to provide written informed consent prior to any study-related procedures and to understand the nature, purpose, and potential risks of the study
- Adult males and females ≥18 years of age at screening
- Life expectancy of at least 3 months
- Histologically or cytologically confirmed unresectable advanced solid tumor (recurrent, metastatic, or locally advanced)
- Disease refractory to, intolerant of, or refusal of standard therapies, including immunotherapy and molecular/biomarker-directed treatments, as determined by the Principal Investigator (PI) or delegate
- Eligible tumor types include:
- Head and neck squamous cell carcinoma
- Thoracic malignancies (small-cell lung cancer, non-small cell lung cancer, esophageal cancer)
- Gastrointestinal malignancies (gastric, liver, colorectal, pancreatic adenocarcinoma)
- Genitourinary malignancies (bladder, renal cell, prostate cancer)
- Gynecologic malignancies (ovarian, endometrial cancer)
- Breast cancer and melanoma
- Evaluable disease per RECIST v1.1
- ECOG performance status 0-1 (or up to 2 at PI discretion)
- Adequate organ function, defined as:
- Total bilirubin ≤1.5 × ULN (≤2.0 × ULN for liver metastases or Gilbert's syndrome)
- AST, ALT, alkaline phosphatase ≤2.5 × ULN (≤5 × ULN if liver metastases, at PI discretion)
This is an extract. Whether you qualify is decided by the trial team against the full criteria, not by reading this page. Read the full eligibility criteria
Where it is running
Running at 3 sites. Listed in: Australia.
Individual hospitals, and whether each is currently open, are listed on the registry record. Sites open and close throughout a trial.
Worth asking your oncology team
Being listed here is not a recommendation, and no one page can tell you whether a trial is right for you. These are the questions it raises.
- Is this trial open at a hospital I could realistically travel to?
- Given my stage, my previous treatment and my tumour's molecular profile, would I be eligible?
- What would I be giving up by joining — is the comparison arm the treatment I would otherwise be having?
- What is already known about the safety of what is being tested?
The source
Registry record NCT07341737, registered by Second Life Therapeutics on ClinicalTrials.gov, a public database run by the US National Library of Medicine. The details on this page come from that record and are only ever as current as the sponsor has kept it.
This is a listing of a registered clinical trial, reproduced for information. It is not a recommendation, this site has no connection to the trial or its sponsor, and being listed here says nothing about whether the treatment works. Talk to your own oncology team before pursuing any trial.
This article summarises published research for general information. It is not medical advice, and it is not a substitute for a conversation with your own oncology team, who know your case. Do not start, stop, or change any treatment or supplement on the basis of what you read here.